西部制药服务
WST
384.02
+1.00
+0.26%
西部制药服务
US · WST
#752 按市值排名
上市于 1970
384.02
+1.00
+0.26%
实时 - 追踪5344个代码 - 心跳于555秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 101.86% 0.00pp
- 机构数量
- 1,003 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund85.00%
Public Company5.26%
Private Company2.84%
Hedge Fund2.42%
Government Pension Fund2.31%
Sovereign Wealth Fund1.28%
Corporate Pension Plan0.81%
VC/PE Fund0.65%
Foundation0.63%
主要股东 截至 2026-06-30
BlackRock
9.45% · 6.65M 股
Vanguard Capital Management, LLC
7.12% · 5.01M 股
Vanguard Portfolio Management, LLC
5.71% · 4.02M 股
FMR
5.01% · 3.52M 股
State Street Global Advisors
4.76% · 3.35M 股
Artisan Partners Limited Partnership
3.43% · 2.41M 股
T. Rowe Price Group, Inc.
3.31% · 2.33M 股
Generation Investment Management LLP
2.88% · 2.03M 股
Geode Capital Management, LLC
2.70% · 1.90M 股
Walter Scott & Partners Limited
1.86% · 1.31M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 12次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Eric Green | Chair, President & CEO | 0.26% |
| Douglas Michels | Independent Director | 0.06% |
| Thomas Hofmann | Independent Director | 0.06% |
| Mark Buthman | Independent Director | 0.06% |
| William Feehery | Independent Director | 0.05% |
| Annette Favorite | Chief Human Resources Officer & Senior VP | 0.03% |
| Myla Lai-Goldman | Independent Director | 0.02% |
| Paolo Pucci | Lead Independent Director | 0.02% |
| Deborah L. Tanner | -- | 0.02% |
| Michel Lagarde | Chief Executive Officer | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Janet Haugen | Director | Other Derivative Acquisition | +44 | -- |
| 2026-09-14 | Annette Favorite | Chief Human Resources Officer & Senior VP | Derivative Exercise and Sale | -7,524 | $89.64–365.00 |
| 2026-09-07 | Michel Lagarde | Chief Executive Officer | Other Derivative Acquisition | +14,750 | -- |
| 2026-09-07 | Michel Lagarde | Chief Executive Officer | Other Derivative Acquisition | +37,048 | $337.75 |
| 2026-09-07 | Annette Favorite | Chief Human Resources Officer & Senior VP | Derivative Exercise and Sale | -8,135 | $83.47–340.81 |
| 2026-08-30 | Michel Lagarde | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-10 | Robert McMahon | Senior Vice President | Derivative Exercise and Sale | -3,109 | $351.37 |
| 2026-08-10 | Robert McMahon | Senior Vice President | Derivative Exercise and Retained | +4,040 | -- |
| 2026-06-29 | Janet Haugen | Director | Other Derivative Acquisition | +46 | -- |
| 2026-05-11 | Shane Campbell | SVP & Chief Proprietary Segment Officer | Derivative Exercise and Sale | -219 | $312.07 |
| 2026-05-11 | Shane Campbell | SVP & Chief Proprietary Segment Officer | Derivative Exercise and Retained | +550 | -- |
| 2026-05-06 | Thomas Hofmann | Independent Director | Intent to Sell (Form 144) | -3,384 | $322.12 |
| 2026-05-03 | Myla Lai-Goldman | Independent Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Robert Friel | Independent Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Janet Haugen | Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Mark Buthman | Independent Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Douglas Michels | Independent Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Deborah L. Tanner | -- | Other Acquisition | +791 | -- |
| 2026-05-03 | Paolo Pucci | Lead Independent Director | Other Acquisition | +791 | -- |
| 2026-05-03 | Stephen Lockhart | Independent Director | Other Acquisition | +791 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
西部制药服务 讨论区 0 条评论